Radius Health Inc. (RDUS) PT Set at $85.00 by Canaccord Genuity

Radius Health Inc. (NASDAQ:RDUS) has been given a $85.00 price objective by investment analysts at Canaccord Genuity in a report issued on Monday. The firm currently has a a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity’s price target would suggest a potential upside of 54.24% from the company’s current price.
A number of other analysts have also recently weighed in on the company. Jefferies Group raised their price objective on Radius Health from $37.00 to $46.00 and gave the stock a “hold” rating in a research report on Monday, August 15th. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a research report on Monday, August 8th. JPMorgan Chase & Co. reissued a “buy” rating and issued a $70.00 price objective on shares of Radius Health in a research report on Friday, August 5th. Cowen and Company reissued a “buy” rating on shares of Radius Health in a research report on Thursday, August 4th. Finally, Maxim Group cut Radius Health from a “hold” rating to a “sell” rating and set a $24.00 price objective for the company. in a research report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Radius Health presently has a consensus rating of “Buy” and a consensus target price of $61.73.

Shares of Radius Health (NASDAQ:RDUS) traded down 0.02% during mid-day trading on Monday, reaching $55.11. The company’s stock had a trading volume of 1,659,474 shares. Radius Health has a 12-month low of $24.75 and a 12-month high of $77.10. The firm’s market cap is $2.37 billion. The firm’s 50-day moving average price is $53.46 and its 200 day moving average price is $40.07.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/radius-health-inc-rdus-pt-set-at-85-00-by-canaccord-genuity.html

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by $0.06. During the same quarter last year, the company earned ($0.61) earnings per share. On average, analysts expect that Radius Health will post ($3.95) EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its position in Radius Health by 5.3% in the first quarter. Geode Capital Management LLC now owns 235,675 shares of the biopharmaceutical company’s stock worth $7,409,000 after buying an additional 11,852 shares during the last quarter. State Street Corp raised its position in Radius Health by 39.9% in the first quarter. State Street Corp now owns 1,588,379 shares of the biopharmaceutical company’s stock worth $49,938,000 after buying an additional 453,302 shares during the last quarter. Wexford Capital LP bought a new position in Radius Health during the first quarter worth $959,000. ING Groep NV raised its position in Radius Health by 159.2% in the first quarter. ING Groep NV now owns 451,486 shares of the biopharmaceutical company’s stock worth $14,181,000 after buying an additional 277,311 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Radius Health by 79.7% in the first quarter. JPMorgan Chase & Co. now owns 147,112 shares of the biopharmaceutical company’s stock worth $4,626,000 after buying an additional 65,259 shares during the last quarter. Institutional investors and hedge funds own 99.91% of the company’s stock.
About Radius Health
Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Receive News & Ratings for Radius Health Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Radius Health Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Be the first to comment on "Radius Health Inc. (RDUS) PT Set at $85.00 by Canaccord Genuity"

Leave a comment

Your email address will not be published.

*